Date: 2011-03-08
Type of information: Grant
Company: Cellectis (France) Etablissement Français du Sang (EFS) (France) Pierre and Marie Curie University (UPMC) (France) Bertin Technologies (France)
Investors: OSEO (France)
Amount: €9.3 million
Funding type: grant
Planned used: OSEO through its Industrial Strategic Innovation Program will provide financial support for StemRed, a collaborative program to produce red blood cells from induced pluripotent stem cells (iPS cells). This program has started on March 1, 2011 and will run for a period of 7 years. It involves Cellectis, Etablissement Français du Sang (EFS), Pierre and Marie Curie University (UPMC), Bertin Technologies and CECS (Centre d’Etude des Cellules Souches). This support is contingent upon the achievement of certain pre-established milestones.
Others:
Therapeutic area: Technology - Services
